Propanc Biopharma (PPCB) AI Stock Analysis

Propanc Biopharma

(NASDAQ:PPCB)

Select Model

Rating:41Neutral

Price Target:$2.00▲(8.70% Upside)

Action:reiterated

Date:10/31/26

The score is pressured primarily by weak financial fundamentals (no revenue, recurring losses, and negative cash flow) and a pronounced bearish technical setup with the price far below key moving averages. Additional downside risk comes from the Nasdaq delisting notice/appeal process, while valuation metrics provide limited support given the negative P/E and no dividend.

Positive Factors

Low leverageThe sharp reduction in debt materially lowers leverage and interest-related pressure, giving the company a cleaner capital structure than in the prior year. This can preserve financial flexibility while management funds oncology development, although ongoing losses remain a constraint.

Negative Factors

Pre-commercial businessThe absence of revenue across the reported periods means the company has not yet demonstrated commercial demand or an operating revenue engine. Its ability to create durable value therefore depends heavily on advancing candidates and eventually obtaining revenue, rather than on an established business base.

Propanc Biopharma (PPCB) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $4.19M
Dividend Yield: ―
Average Volume (3M): 189.13K
Price to Earnings (P/E): -0.1
Beta (1Y): -0.64
Revenue Growth: ―
EPS Growth: 98.74%
Country: US
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Propanc Biopharma Business Overview & Revenue Model

Company Description

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic c...

Propanc Biopharma Financial Statement Overview

Summary

Early-stage biotech profile with no revenue across 2021–2026, persistent and volatile losses (notably large in 2025 and still sizable in 2026), and consistently negative operating/free cash flow. Balance sheet leverage is a relative positive with sharply reduced debt and recently positive equity, but equity declined from 2025 to 2026 and ongoing cash burn implies continued reliance on external financing.

Income Statement

8Very Negative

Balance Sheet

42Neutral

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-18.41M	-18.41M	-58.34M	-1.26M	-2.26M	-2.14M
Net Income	-18.86M	-18.86M	-58.92M	-1.82M	-2.66M	-2.66M
Balance Sheet
Total Assets	12.78M	12.78M	19.63M	72.36K	60.33K	81.65K
Cash, Cash Equivalents and Short-Term Investments	832.01K	832.01K	12.09K	21.09K	10.05K	4,067
Total Debt	509.12K	48.31K	1.73M	948.27K	545.92K	1.04M
Total Liabilities	3.38M	3.38M	5.73M	3.85M	3.18M	3.11M
Stockholders Equity	9.40M	9.40M	13.91M	-3.78M	-3.12M	-3.02M
Cash Flow
Free Cash Flow	-5.69M	-5.68M	-405.17K	-935.12K	-1.11M	-1.44M
Operating Cash Flow	-5.69M	-5.68M	-405.17K	-935.12K	-1.11M	-1.44M
Investing Cash Flow	-4,942	-4,933	0	0	0	0
Financing Cash Flow	6.46M	6.46M	490.76K	941.89K	1.11M	1.49M

Propanc Biopharma Technical Analysis

Technical Analysis SentimentNegative

Last Price1.84

Price Trends

50DMA6.72Negative

100DMA10.64Negative

200DMA23.44Negative

Market Momentum

MACD-1.27Negative

RSI21.17Positive

STOCH1.97Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PPCB, the sentiment is Negative. The current price of 1.84 is below the 20-day moving average (MA) of 3.47, below the 50-day MA of 6.72, and below the 200-day MA of 23.44, indicating a bearish trend. The MACD of -1.27 indicates Negative momentum. The RSI at 21.17 is Positive, neither overbought nor oversold. The STOCH value of 1.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PPCB.

Propanc Biopharma Risk Analysis

Propanc Biopharma disclosed 51 risk factors in its most recent earnings report. Propanc Biopharma reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Covid-19Q1, 2021

Propanc Biopharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

PPCB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLRB	48Neutral	$11.39M	-0.26	-165.71%	―	―	77.68%
MBRX	46Neutral	$8.29M	-0.02	-816.56%	―	―	85.06%
NCNA	42Neutral	$4.35M	-0.25	-41.95%	―	―	99.50%
PPCB	41Neutral	$1.90M	-0.06	-167.51%	―	―	98.74%
ONCO	33Underperform	$3.30M	-0.06	-91.95%	―	-51.33%	99.22%

* Healthcare Sector Average

Performance Comparison

PPCB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PPCB	Propanc Biopharma Inc	1.84	-280.66	-99.35%
CLRB	Cellectar Biosciences Inc	1.21	-2.09	-63.48%
MBRX	Moleculin Biotech	7.90	-251.95	-96.96%
NCNA	Nucana Plc	1.01	-2.93	-74.37%
GNPX	Genprex	2.24	-114.36	-98.08%
ONCO	Onconetix Inc	0.56	-157.44	-99.64%

Propanc Biopharma Corporate Events

Delistings and Listing ChangesRegulatory Filings and Compliance

Propanc Biopharma Appeals Nasdaq Delisting After Bid Shortfall

Negative

Oct 29, 2026

On October 23, 2026, Propanc Biopharma received a notice from Nasdaq’s Listing Qualifications Department stating that the company’s common stock had failed to meet the $1.00 minimum bid price requirement for continued listing on The Nasda...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Propanc Biopharma AI Stock Analysis